Chinese authorities approved Zhuhai Rundu Pharmaceutical's (SHE:002923) supplementary drug application for its valacyclovir hydrochloride tablets for herpes simplex, according to a Friday filing with the Shenzhen bourse.
Herpes simplex causes painful blisters or sores and is usually transmitted through skin-to-skin contact, and is treatable but not curable, the World Health Organization said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments